Abstract
Basal cell carcinoma (BCC) is one of the most common human cancers. Most cases of BCC are amenable to surgical and topical treatments with excellent prognosis if diagnosed timely and managed appropriately. However, in a small percentage of cases, it could be locally advanced BBC (laBCC) and not amenable to surgery or radiation, including recurrent, large tumors or tumors that invade deeper tissue. Hedgehog inhibitors (vismodegib and sonidegib) are approved as the first-line treatment of laBCC. PD-1 inhibitor immunotherapy (cemiplimab) is indicated for cases that progressed on or could not tolerate hedgehog inhibitors or when hedgehog inhibitors are contraindicated. Given the modest response and bothersome side effects of some of the agents above, there are reports of novel treatments, and clinical trials are currently evaluating multiple agents.
Original language | English (US) |
---|---|
Article number | 216821 |
Journal | Cancer Letters |
Volume | 589 |
DOIs | |
State | Published - May 1 2024 |
Keywords
- Hedgehog inhibitors
- Locally advanced basal cell carcinoma
- PD-1 inhibitors
ASJC Scopus subject areas
- Oncology
- Cancer Research